• TRAF2 Competition by CD40 and STING Drives IRF4 B Cell Activ

  2026-05-20

  This study reveals that competitive binding of CD40 and STING with TRAF2 orchestrates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). These findings establish TLS presence as an independent prognostic marker and clarify the molecular mechanisms that regulate adaptive immunity in ESCC, providing a foundation for future biomarker and therapeutic development.

• Fluorinated CXCR4 Inhibitor A1 Surpasses AMD3100 in Colorect

  2026-05-20

  Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, demonstrating superior efficacy over AMD3100 in preclinical colorectal cancer models. Their integrated approach, spanning molecular simulations to in vivo analysis, highlights the therapeutic promise of advanced small-molecule CXCR4 antagonists for cancer metastasis inhibition.

• Deferoxamine Mesylate: Precision Iron Chelation for Metaboli

  2026-05-19

  Explore how Deferoxamine mesylate, a leading iron-chelating agent, enables advanced study of iron metabolism and cellular stress adaptation. This article uniquely integrates new insights on nutrient sensing and lysosomal dynamics to guide next-generation assay design.

• DiscoveryProbe Protease Inhibitor Library: Applied Workflows

  2026-05-19

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput exploration of protease biology, delivering robust, reproducible results for drug discovery and mechanistic research. This guide details practical workflows, troubleshooting strategies, and advanced use-cases, spotlighting how APExBIO's curated inhibitor collection elevates experimental precision across apoptosis, cancer, and infectious disease studies.

• BIRB 796 (Doramapimod): Applied p38α MAPK Inhibition in Infl

  2026-05-18

  BIRB 796 (Doramapimod) enables precise, reproducible modulation of p38α MAPK activity for advanced inflammation and apoptosis assays. Backed by recent mechanistic breakthroughs, this highly selective inhibitor from APExBIO empowers robust experimental workflows and troubleshooting in both cell-based and in vivo research.

• Circ-ECH1 Regulates Ntrk2 via miR-708-5p Competition in BPD

  2026-05-18

  This study identifies circ-ECH1 as a regulator of Ntrk2 expression in bronchopulmonary dysplasia (BPD) by competitively binding miR-708-5p. The findings highlight a novel circRNA-mediated pathway that influences cell survival and fibrosis in hyperoxia-exposed lung cells, suggesting new molecular targets for BPD intervention.

• Dorsomorphin (Compound C): Optimizing AMPK and BMP Pathway I

  2026-05-17

  Dorsomorphin (Compound C) provides researchers with precise control over AMPK activity and BMP signaling, empowering advanced studies in autophagy, iron metabolism, and cellular differentiation. This article delivers workflow-driven protocols, troubleshooting strategies, and direct translation of recent findings into practical assay enhancements, setting APExBIO’s Dorsomorphin apart for reproducibility and experimental clarity.

• Triamcinolone: Technical Guidance for Glucocorticoid Researc

  2026-05-16

  Triamcinolone is a synthetic glucocorticoid agonist optimized for in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. It addresses the need for precise modulation and reproducible handling in anti-inflammatory and immunosuppression studies, but is not suitable for clinical or diagnostic use.

• L1023 Anti-Cancer Compound Library: Workflow Optimization in

  2026-05-15

  The L1023 Anti-Cancer Compound Library empowers rapid, reproducible high-throughput screening of targeted oncology agents, including kinase and MCL1 inhibitors. By integrating practical workflow refinements and troubleshooting rooted in recent literature, researchers can accelerate discovery and surmount resistance mechanisms in cancer models.

• Clathrin-Mediated Entry of Spiroplasma eriocheiris into Dros

  2026-05-15

  This study reveals that Spiroplasma eriocheiris invades Drosophila S2 cells primarily through clathrin-mediated endocytosis and macropinocytosis, with cytoskeletal integrity playing a key role. These mechanistic findings clarify the cellular entry pathways of S. eriocheiris and inform the design of infection models and endocytosis assays.

• Tofacitinib Reverses GM-CSF-Driven Mitochondrial Dysfunction

  2026-05-14

  This study uncovers how tofacitinib (CP-690550) uniquely reverses both inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. By suppressing the STAT5 pathway and restoring regulatory macrophage phenotypes, tofacitinib demonstrates mechanistic effects not observed with anti-TNF, anti-IL6R, or metabolic inhibitors, informing new avenues for immune modulation research.

• Carfilzomib (PR-171): Redefining Proteasome Inhibition Strat

  2026-05-14

  This thought-leadership article unpacks the mechanistic depth and translational significance of Carfilzomib (PR-171) as an irreversible proteasome inhibitor in cancer research. Integrating the latest evidence on proteasome inhibition synergy, apoptosis induction, and multi-modal cell death, it provides strategic guidance for translational researchers seeking to optimize experimental outcomes. Key protocol parameters, competitive landscape analysis, and a forward-looking vision for next-generation combination therapies are discussed, bridging APExBIO’s best-in-class reagent with actionable insights far beyond typical product pages.

• PLAC1 as a Prognostic Biomarker and Target in ccRCC: New Ins

  2026-05-13

  The referenced study identifies PLAC1 as a prognostic biomarker and actionable molecular target in clear cell renal cell carcinoma (ccRCC), demonstrating its high expression correlates with poor prognosis. Using high-throughput virtual screening, the authors discovered small-molecule inhibitors that suppress PLAC1, suggesting novel therapeutic opportunities for ccRCC and informing precision anti-cancer drug discovery.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-13

  This study identifies IGF2BP3 as a dominant m6A reader that stabilizes FZD1/7 transcripts, activating β-catenin signaling and enhancing stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). Disrupting the IGF2BP3–FZD1/7 axis sensitizes cancer stem cells to chemotherapy, offering a new therapeutic target.

• KR-12 Human Antimicrobial Peptide: Protocols and Biofilm Sol

  2026-05-12

  KR-12, the minimal human antimicrobial peptide, delivers targeted anti-biofilm and immunomodulatory action with minimal cytotoxicity, setting it apart from broader-spectrum AMPs. This practical guide synthesizes validated workflows, troubleshooting, and data-backed insights to help researchers maximize the translational impact of KR-12 (human) TFA in infection and inflammation models.

15325 records 8/1022 page Previous Next First page 上5页 678910 下5页 Last page